June 21, 2005 NASD OTC-BB: MRDAF

MERIDIAN APPLIES FOR CANADIAN APPROVAL DIGITAL PULSE ANALYZER

Meridian Co. Ltd. ("Meridian" or the "Company") (OTC BB: MRDAF) is pleased to announce that it has commenced the process to obtain all necessary regulatory approvals to sell its premier product, the Digital Pulse Analyzer (¡°DPA¡±) in Canada. Sales in the United States began in late 2004 and have been steadily increasing. The Company wants to capitalize on this growing success.

Meridian is excited to launch the DPA in Canada, as the corporate and distribution office is located in Vancouver, British Columbia. Recently, at the Northwest Naturopathic Convention held April 22 - 24 in Vancouver, there was serious interest expressed by local practitioners. In addition, the Vancouver office has had numerous requests to purchase the DPA, and as a result the Company is anticipating a lucrative market.

The Company¡¯s target market will be health care professionals and neutraceutical companies. Meridian¡¯s FDA approved, non-invasive DPA is a perfect fit as it¡¯s a proven method of detecting whether a particular treatment option, such as natural supplementation, is effective.

The natural health products industry is one of the fastest growing markets in the developed world and Canada is following this global trend. The use of vitamins, minerals, probiotics, herbal remedies and supplements in Canada increased dramatically during the past decade and has remained extremely popular entering into the twenty-first century.

In North America, consumers spend billions annually on nutritional supplements. A growing health conscious and self-care minded population are becoming increasingly interested in using supplementation as a way to stay healthy. Cutting-edge medical devices, such as the DPA, will add credibility to health products and prescribed lifestyle changes, and could successfully contribute to a new flux in demand for superior products. Canadians are expected to be just as receptive as American¡¯s in utilizing this innovative technology to ensure their lifestyle changes are meeting their healthcare needs.

The DPA has two software features, the first measuring arterial compliance and the second measuring the balance of the autonomic nervous system. Therefore, the efficacy of treatment options for arterial compliance or stress related issues can be demonstrated by utilizing the technology of the DPA.

More About: Digital Pulse Analyzer ("DPA")

The "DPA" accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA approved device is inexpensive, non-invasive, and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.

The Company feels that use of the "DPA" can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention, and ultimately assist to decrease the associated financial costs placed on the health care industry. Cardiovascular disease is the #1 killer in the United States with an estimated economic cost of approximately $298 billion.

More About: Heart Rate Variability ("HRV")

HRV measures the variation in the length of the intervals, measured in milliseconds between heart beats. Studies have shown that low HRV is a valuable indicator or predictor of illness and mortality, especially sudden cardiac death. Other chronic conditions associated with low HRV can include: depression, anxiety, coronary artery disease, congestive heart failure, hypertension, and diabetes. It has been shown that all of these chronic conditions also have a strong linkage to silent inflammation.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing, and sales of integrative medical diagnostic equipment. The company sells its products and equipment to a wide array of customers in the global health care industry. The company presently holds a total of 18 worldwide patents on its technology, and has received FDA, as well as other international regulatory approvals for many of its products.

Meridian is committed to the ongoing global research and advancement of integrative medical products that contribute to the better health of humanity.

For further product information please contact:
Belgium Medical Inc. - North American Distribution Office
Debbie Williams, President
1-877-738-8119